ImageneBio, Inc.
IMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001835579
In the last 90 days, ImageneBio, Inc. insiders filed 0 open-market purchases and 1 sale; 35 institutions reported holding it in 13F filings for Q2 2026, worth $36.8M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding ImageneBio, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 42 | 39 | −3 |
| Shares | 21.1M | 20.9M | −184.9K (−0.9%) |
| Value | $293.2M | $271.8M | −$21.4M (−7.3%) |
New holders (2)
Institutions that held ImageneBio, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 113 | $1.00K | 0.00% |
| UBS Group AG | 85 | $1.00K | 0.00% |
Sold out (5)
Institutions that held ImageneBio, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Nantahala Capital Management, LLC | 349,660 | $4.91M |
| Alyeska Investment Group, L.P. | 100,000 | $1.40M |
| Millennium Management LLC | 61,561 | $864.0K |
| Pinz Capital Management, LP | 25,390 | $356.0K |
| D. E. Shaw & Co., Inc. | 11,984 | $168.0K |